Sign in / Join Now
ETFs & Funds
$40M IPO is just another attempt to fleece investors. This company is a complete scam.
Add a reply...
Latest StockTalks »
people get RTRX breaking news and analysis by email alert.
Get email alerts on RTRX »
Get latest price
From other sites
Retrophin To Present Additional Data From Phase 2 DUET Study Of Sparsentan In Late-Breaking Oral Session At ASN Kidney Week 2016
at TheStreet (Fri, 11:04AM)
Retrophin To Report Third Quarter 2016 Financial Results
at TheStreet (Thu, 4:30PM)
Dr. Alvin Shih Departing Retrophin To Lead Biotechnology Start-Up
at TheStreet (Oct 6, 2016)
Retrophin Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
at TheStreet (Sep 30, 2016)
Retrophin To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
at TheStreet (Sep 14, 2016)